1/10/2017
As many pediatric practices have been aware, the popularity of Sanofi Pasteur’s DtaP/IPV/Hib combination vaccine, Pentacel® put a significant demand on supply. Although Pentacel was never placed on back order, order allocations was the temporary solution while Sanofi Pasteur, the vaccine’s manufacturer diligently focused on the situation.
Sanofi Pasteur announced yesterday very welcome news regarding Pentacel supply and availability. Effective Immediately, order allocations have finally been officially lifted.
Pentacel® is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b. Pentacel vaccine is approved for use as a four dose series in children 6 weeks through 4 years of age.
Quadracel® supply is also now fully available. Quadracel is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis. A single dose of Quadracel is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel and/or DAPTACEL vaccine.